Indication

Treatment of primary biliary cholangitis (PBC), including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.

Medicine details

Medicine name:
seladelpar (Livdelzi)
SMC ID:
SMC2835
Pharmaceutical company
Gilead Sciences Ltd
BNF chapter
Gastro-intestinal system
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
TBC